Thai Medical Tourism: Acuity Mix and the International-Cohort Recovery
How acuity tiers (high-acuity cardiology, oncology, orthopaedics; mid-acuity cosmetic; dental and wellness) and source cohorts (Middle East, China, CLMV, ASEAN) split across BDMS, Bumrungrad, BCH and the JCI-accredited long tail in Thailand's structurally cheaper international-care market.
Key takeaways
- 1
Thai medical tourism is structurally JCI-anchored at ~3.5- international patient visits and roughly per year (MoPH, Deloitte triangulation).
- 2
Acuity splits roughly high-acuity (cardiology, oncology, orthopaedics), mid-acuity, wellness and IVF, dental and check-up.
- 3
BDMS captures ~ of international flow across Bangkok Hospital, Samitivej, Phyathai brands; Bumrungrad ~; long tail of JCI hospitals ~.
- 4
2024 recovery is uneven: Middle East cohort returned structurally above pre-pandemic; Chinese cohort sits near of 2019 peak.
- 5
Pricing structurally below US, UK, Singapore at JCI-accredited tertiary centres; Thai hospitality and specialty depth defend share.
Executive summary
Thai medical tourism is one of Asia's largest international-care industries, anchored by JCI accreditation density and a structural pricing gap of roughly below US, UK, and Singapore equivalents. MoPH triangulation places aggregate volume at ~3.5- international patient visits per year and revenue at ~, with Bangkok the dominant gateway and a JCI-accredited long tail across Phuket, Chiang Mai, and Pattaya.[, , ]
Acuity mix is the analytic centrepiece. High-acuity cardiology, oncology, and orthopaedics drive roughly of international revenue, led by Middle East and CLMV cohorts that travel for tertiary care unavailable or rationed at home. Mid-acuity cosmetic, gynaecology, and gastro account for ~, wellness and IVF for ~, and dental, check-up, and day-case for ~. The high-acuity tier is BDMS and Bumrungrad territory; the wellness and dental tiers fragment across BCH, RAM, Praram9, and dozens of specialty clinics.[, , ]
The 2024 recovery is structurally uneven. Middle East patient flow returned above pre-pandemic levels, supported by family-accompanied stays, repeat episodes, and Bangkok hospital concierge depth. Chinese cohort recovery lags at roughly of 2019 peak, with Hainan domestic medical tourism, Korean cosmetic competition, and outbound travel friction all weighing. For investors, BDMS and Bumrungrad are the cleanest listed exposures; BCH offers mid-market reach.[, ]
Acuity mix of Thai international medical care (% of revenue)
High-acuity (cardiology, oncology, orthopaedics)
Share %
Lead cohort, operators
Middle East, CLMV; BDMS Heart, Wattanosoth Cancer, Bumrungrad specialty centres
Mid-acuity (cosmetic, gynaecology, gastro)
Wellness, longevity, IVF, executive
Share %
Lead cohort, operators
Western, Japanese expat, ASEAN; BDMS Wellness, Bumrungrad Vitallife, Jetanin
| Acuity tier | Share % | Lead cohort, operators |
|---|---|---|
| High-acuity (cardiology, oncology, orthopaedics) | 38% | Middle East, CLMV; BDMS Heart, Wattanosoth Cancer, Bumrungrad specialty centres |
| Mid-acuity (cosmetic, gynaecology, gastro) | 26% | China, ASEAN; Yanhee, BDMS Phyathai, Samitivej |
| Wellness, longevity, IVF, executive | 20% | Western, Japanese expat, ASEAN; BDMS Wellness, Bumrungrad Vitallife, Jetanin |
| Dental, check-up, day-case | 16% | Regional ASEAN, Australian, Western retiree; BIDC, BCH, Praram9 |
Operator concentration in international care (% of high-spend international flow)
BDMS group (Bangkok Hospital, Samitivej, Phyathai, Paolo, BNH)
Share %
Role
Largest hospital network; multi-brand coverage from premium Sukhumvit to regional
Bumrungrad International (SET: BH)
Share %
Role
International-cohort flagship; ~1.1M international encounters, 190+ nationalities
Samitivej (BDMS premium specialty brand)
Share %
8%
Role
Premium paediatrics, orthopaedics, women's health within BDMS
Bangkok Chain Hospital (SET: BCH, Kasemrad)
Share %
9%
Role
Mid-market network with regional reach and mid-acuity exposure
| Operator | Share % | Role |
|---|---|---|
| BDMS group (Bangkok Hospital, Samitivej, Phyathai, Paolo, BNH) | 42% | Largest hospital network; multi-brand coverage from premium Sukhumvit to regional |
| Bumrungrad International (SET: BH) | 18% | International-cohort flagship; ~1.1M international encounters, 190+ nationalities |
| Samitivej (BDMS premium specialty brand) | 8% | Premium paediatrics, orthopaedics, women's health within BDMS |
| Phyathai (BDMS regional brand) | 7% | Greater-Bangkok regional brand within BDMS |
| Bangkok Chain Hospital (SET: BCH, Kasemrad) | 9% | Mid-market network with regional reach and mid-acuity exposure |
| Other JCI hospitals (Praram9, Thonburi, RAM, BNH) | 16% | Long tail of JCI-accredited operators capturing residual flow |
Analyst framing
Why this report matters
Unlock the full report
Need more than the web report? Ask for a scoped export or source appendix.
Every report keeps visible citations and source metadata. Terms.
Related reports
BCH Bangkok Chain Hospital: Mid-Market Positioning and IPO Aftermath
BCH (SET: BCH) booked THB 11.83B revenue and THB 1.28B net profit in FY2024 across 16 hospitals plus 2 polyclinics (2,323 licensed beds). The franchise sits between BDMS premium (59 hospitals, 8,841 beds) and government tier, with c.7.7% share of the Social Security Office (SSO) private-hospital patient base β roughly one-third of revenue from SSO contracts. Twenty-one years post-2004 SET listing, the strategic question is whether Kasemrad mid-market scale can compound margin without conceding the SSO franchise.
Open report β
The Thai Private Hospital Tier Map: BDMS Empire, Bumrungrad Premium, and Bangkok Hospital Network
Thailand's private-hospital industry reaches estimated THB 280-360B annual revenue across multi-tier structure. BDMS (Bangkok Dusit Medical Services, SET-listed parent, founded 1972 by Prasert Prasarttong-Osoth and Chudchai Khanhulok) is structural Thai market leader operating ~50+ hospitals across multi-brand portfolio: Bangkok Hospital network (~25+ hospitals including flagship Bangkok Hospital Soi Soonvijai), Samitivej (~10 hospitals including Samitivej Sukhumvit, Samitivej Srinakarin), BNH (Bangkok Nursing Home, premium expat), Phyathai (~5 hospitals), Paolo (mid-tier ~10 hospitals). BDMS revenue THB 105B+ FY2024 with international-patient share material. Bumrungrad International (BH, SET-listed) premium-international-patient-anchored single-flagship with USD 1B+ annual revenue; international-patient share ~50%+ of revenue. Bangkok Chain Hospital (BCH, SET-listed) mid-market multi-province operator. Independent / smaller-listed operators: Praram 9 Hospital (PR9, SET-listed), Vibhavadi Hospital (VIBHA, SET-listed), Vichaiyut Hospital, Mahachai Hospital, Sikarin Hospital. International-patient mix structurally important: BDMS, Bumrungrad ~30-40% of premium-tier revenue from international cohorts (Middle East, ASEAN+China, Western expat-and-tourist). Watch BDMS provincial-expansion and Bumrungrad international-patient recovery 2024-2026.
Open report β
Thai Aging Population: Pension Reform and the Private-Healthcare Demand Curve
Thailand officially entered complete aged-society status in 2021 with people aged 60+ comprising 20% of the population per Krungsri Research; the proportion is projected to reach 30% by 2030. The UN expects 65+ to exceed 20% of population by 2029 β Thailand will then qualify as super-aged. Pension reform is in motion: a Royal Decree on 15 November 2024 created the Employee Welfare Fund (EWF) β a new supplementary provident-fund programme launched 1 October 2025 per the US SSA International Update. The Office of the Civil Service Commission is conducting a feasibility study to extend civil-servant retirement age from 60 to 65 per Nation Thailand and Pension Policy International. Per the JIL Thailand seminar paper, Thailand needs inclusive labour-reform to maintain workforce participation as the demographic transition advances. WHO Thailand supports long-term-care financing and home-based-care models. The Social Security Fund's pension benefits are structurally insufficient for retired-worker income replacement; nearly half the population works in the informal sector and lacks effective pension coverage. The structural-investor read: SET-listed hospital groups (BDMS, Bumrungrad International) face structural demand tailwind from private-healthcare aging-population spend; long-term-care insurance market is structurally underdeveloped β material 2026-2030 growth opportunity.
Open report β
Thai Digital Health: Telemedicine, Doctor Raksa, and Hospital Adoption
Thai digital health is structured across telemedicine consumer apps, hospital EMR systems, AI-pathology and clinical-decision-support pilots, and government National Health Security Office (NHSO) digital agenda. Major telemedicine apps: Doctor Raksa (Telehealth, founded 2015, primary-care consult plus pharmacy), MorDee (LINE-integrated telemedicine), Chiiwii Live (mental health), Pasaya (multi-specialty), Health at Home (home-care booking). Hospital EMR adoption: BDMS group (BDMS, Samitivej, Phyathai, Bangkok Hospital network) operates BDMS Connect digital-platform; Bumrungrad on legacy, new digital integrations; Praram 9, Phyathai 2, private-tier hospitals across digital-front-end variants. AI-pathology pilots: BDMS-IBM Watson (legacy), Chulalongkorn AI-pathology research, Mahidol Faculty of Medicine projects. PDPA applies to health-data with explicit-consent requirement. FDA Thailand regulates digital therapeutics and software-as-medical-device (SaMD). NHSO 30-Baht universal-coverage scheme expanding digital channels for consultation, prescription refill, chronic-disease management. The structural-investor read: telemedicine adoption is post-COVID structural; hospital EMR digital-front-end builds; AI-pathology pilots scaling.
Open report β